Ann: Change in substantial shareholder interest, page-19

Some may be a bit slow at understanding the relationship with Paul Hopper and GDC-0084.   But all one can say without being slanderous or liable is that Paul Hopper and Leslie Chong had a difference of opinion on  how the company should be run. KZA management has not followed the usual pattern that normally occurs when PH gets involved with company.   Suffice to say one has stayed her position in shares although no longer a consultant after around 12 months and the other left the building around 2 months into the relationship way back in 2016......and after that, literal burning his remuneration packages  down to half their value.   A scorched earth policy to comes to picture but hey........ it is a free world and people can do what they want with their pocket money. But what is not in dispute and the irony here is delicious, is both thoroughly believed that GDC-0084 was such a winning drug it was their idea to brokerage it out to KZA.   Leslie Chong all though the CEO of another company is still strong advocate of GDC-0084 always has and always will. Without her efforts KZA would have never got a foot in the door with genentech. She has not sold either milestone payments.

SYDNEY, Oct. 31, 2016 "Paul Hopper, a highly-experienced life sciences executive, and Leslie Chong, who was formerly Clinical Program Lead for GDC-0084 at Genentech, both shareholders of Glioblast, will become consultants to Novogen and will advise on clinical development."
https://www.medianet.com.au/releases/116684/